Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval - Pharmaceutical Technology

Ionis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage. Ionis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage. In Tryngolza, Ionis is hoping to break the blockbuster ceiling for the first time with a wholly owned product. Credit: Shutterstock/Cagkan Sayin.com. Earlier this year, Ionis’ CEO Brett Monia said that Tryngolza (olezarsen) would become the company’s first fully owned blockbuster drug, with that forecast having just become more likely following a US label expansion. The US Food and Drug Administration (FDA) has approved Tryngolza as an adjunct…

Source: Pharmaceutical Technology